Navigation Links
Ethical Pharmaceuticals Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020

Albany, New York (PRWEB) August 26, 2014

Ethical pharmaceuticals or prescription drugs are those licensed drugs that are regulated by various legislation to require a written medical prescription before it can be procured. An ethical pharmaceutical product is only sold by pharmacists when it has been approved by a written medical prescription from a registered medical practitioner. The term prescription drugs or ethical pharmaceutical is usually used to distinguish the products from over-the-counter drugs—drugs that can be obtained without a written medical prescription. However, varied jurisdictions have varied definitions of what constitutes an ethical pharmaceutical. At present, ethical pharmaceuticals market is highly profitable as well as a risky market venture. The market is expected to be profitable owing to the upcoming patent expiries of many blockbuster drugs; and risky because of the involvement of many established and multinational companies who have built a global recognition for their safe and effective products.

Some of the top selling therapeutic classes of ethical pharmaceuticals are as follows:

  • Lipid regulators
  • Narcotic analgesics
  • ACE inhibitors
  • Respiratory agents
  • Diuretics
  • Calcium antagonists
  • Hormonal contraceptives
  • Penicillin
  • Vitamin and minerals
Get report sample PDF copy here:

In terms of geography, North America is the largest market for ethical pharmaceuticals owing to the large population base suffering from various chronic diseases and increasing number of elderly population. According to the American Cancer Society, in 2013, approximately 1,660, 290 new cases of cancer were identified and diagnosed in the U.S. Additionally, according to the Centers for Disease Control and Prevention (CDC), in 2012, 35.1% percent of adults with age over 20 years and over are obese. It is expected that in the coming years that emerging markets such as China, India, Russia, Mexico, and Brazil are going to lead the market with a market share amounting to nearly one-third of the global pharmaceutical market under the influence of economic liberalization, increase in elderly population, increase in chronic diseases, and huge population of China and India.

One of the primary factors driving the growth of the global ethical pharmaceuticals market are increasing incidence rate of chronic diseases linked with unhealthy lifestyles and increasing geriatric population. Moreover, factors such as high demand for safe and effective treatment regimens are also driving the growth of this market. Furthermore, increasing burden of chronic medical conditions such as cancer, diabetes, and high blood pressure among the geriatric population, and increased focus on retaining superior quality of life are some of the factors contributing in the growth of the ethical pharmaceuticals market.

Additionally, at present, the global pharmaceutical market is a multinational and complex industry, with products aimed at the improvement and maintenance of people’s health. The overall drugs market is occupied by a broad spectrum of pharmaceutical companies ranging from established multinationals to emerging generic drug companies. It has been observed that in order to commercialize a drug in the market, the average expense is more than USD 800 million to the pharmaceutical companies. However, the ethical pharmaceutical segment of the overall drug industry is under risk from many sources, mainly from the generic drug industry, which can be a restraining factor for the market.

Currently, the global ethical pharmaceuticals market is a highly fragmented industry due to the involvement of many established and emerging players in the overall market. Some of the major players involved in the market are AstraZeneca plc, Bristol-Myers Squibb, Eli Lilly and Company, GlaxoSmithKline plc, Johnson & Johnson, Merck & Co., Inc., Mylan, Inc., Novartis AG, Pfizer, Inc., Sanofi S.A., and Teva Pharmaceutical Industries Ltd. amongst others.

This research report analyzes this market on the basis of its market segments, major geographies, and current market trends. Geographies analyzed under this research report include:

  • North America
  • Asia Pacific
  • Europe
  • Rest of the World
Early buyers will receive 10% customization on this report.

This report provides comprehensive analysis of

  • Market growth drivers
  • Factors limiting market growth
  • Current market trends
  • Market structure
  • Market projections for upcoming years
This report is a complete study of current trends in the market, industry growth drivers, and restraints. It provides market projections for the coming years. It includes analysis of recent developments in technology, Porter’s five force model analysis, and detailed profiles of top industry players. The report also includes a review of micro and macro factors essential for the existing market players and new entrants, along with detailed value chain analysis.

Reasons for buying this report:

  • This report provides pin-point analysis for changing competitive dynamics.
  • It provides a forward looking perspective on different factors driving or restraining market growth.
  • It provides a six-year forecast assessed on the basis of how the market is predicted to grow.
  • It helps in understanding the key product segments and their future.
  • It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors.
  • It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments.
  • It provides distinctive graphics and exemplified SWOT analysis of major market segments.
Sheela AK
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA/Canada Toll Free: 866-552-3453
Email: sales(at)transparencymarketresearch(dot)com
More Pharmaceutical Reports at

Read the full story at

Source: PRWeb
Copyright©2014 Vocus, Inc.
All rights reserved

Related medicine news :

1. The Lancet: Experimental Ebola drugs must be fairly distributed and tested ethically in clinical trials
2. Exploring a legal and ethical gray area for people with dementia
3. The Cleft Palate–craniofacial Journal Marks 50 Years of Research With an Ethical Review
4. New Research on Skin Benefits of Alpha Lipoic Acid Announced by Ethical Alternative Products
5. Marketing loans for fertility treatments raises ethical concerns
6. Ethical research with minorities
7. Quorum Review’s J. Claire Carbary Presents at PRIM&R’s 2013 Advancing Ethical Research Conference
8. Educannon, Ethical Electric, Dorsata, and RideScout Take Top Honors at Challenge Cup D.C.
9. Unpublished trial data violates an ethical obligation to study participants, say researchers
10. HIV answers raise new ethical questions
11. Heart-Centered Marketing and Business Coach Louisa Chan Publishes New Guide on Ethical Business Marketing for Coaches, Trainers, Tutors and Training Providers
Post Your Comments:
(Date:11/26/2015)... ... 2015 , ... The Catalent Applied Drug Delivery Institute today ... dose form selection in early phase drug development. The first of these is ... together the UK’s emerging life sciences companies, corporate partners, and investors, at Milton ...
(Date:11/26/2015)... San Antonio, TX (PRWEB) , ... November 26, 2015 , ... ... accomplishment! On November 19, 2015, our surgeons performed their 6,000th free flap breast ... Ledoux , “We wake up every day excited to rebuild lives and it’s an ...
(Date:11/26/2015)... ... November 26, 2015 , ... Pixel Film ... trailer titles with ProTrailer: Vintage. This newly styled ProTrailer pack comes with 30 ... with any font, giving users limitless opportunities to stylize and create designs quickly ...
(Date:11/26/2015)... ... ... Inc., developer and distributor of the world-class Asterisk based contact center software Q-Suite, announces ... new Q-Suite 6 platform is based on the latest Java Enterprise standards. By conforming ... of software for many key components of the suite. Much of the suite runs ...
(Date:11/25/2015)... ... November 25, 2015 , ... As part ... For Empowerment ™ attracts volunteers together who want to combine talents and resources ... key stakeholders in the process. The non-profit launched its first major fundraiser on ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... 2015 ... the  "2016 Future Horizons and Growth ... Monitoring (TDM) Market: Supplier Shares, Country ...  report to their offering.  --> ... addition of the  "2016 Future Horizons ...
(Date:11/26/2015)... , November 26, 2015 ... addition of the "Radioimmunoassay Market by ... (Hospital, Pharmaceutical Industry, Academics, Clinical Diagnostic Labs), ... Global Forecast to 2020" report to ... has announced the addition of the ...
(Date:11/25/2015)... , Nov. 25, 2015  Amgen (NASDAQ: AMGN ... Application (BLA) with the United States ... 501, a biosimilar candidate to Humira ® (adalimumab). ... application submitted to the FDA and represents Amgen,s first ... Sean E. Harper , M.D., executive vice president of ...
Breaking Medicine Technology: